Consano Bio to Present Clinical Development of C-1101 for Chronic Sciatica at 2026 BIO International Convention

The company recently announced initiation of a Phase 1 trial for C-1101, a potential first-in-class, non-opioid therapy for chronic sciatica BURLINGTON, MA — June 10, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that Andrew Hall, Chief Executive Officer will present at BIO International Convention, being held June 22-25, 2026, in San Diego, California. Event: 2026 BIO International Convention Date and Time: Monday, June 22 3:30 PM Theater 1 Location: San Diego Convention Center Presenter: Andrew Hall, Chief Executive Officer During the conference, Mr. Hall will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy and anticipated milestones. The company recently initiated Phase 1 clinical trial of C-1101 (C-1101-101, NCT07264270) in patients with painful lumbosacral radiculopathy (LSR), also known as chronic sciatica. C-1101 is a platelet-derived, multi-protein therapeutic designed to be delivered locally to the site of nerve injury. By targeting the inflammatory and biological processes that contribute to persistent nerve damage, Consano aims to develop a disease-modifying approach that addresses the root causes of chronic sciatica rather than masking symptoms. About Consano Bio Consano Bio is a clinical-stage biotechnology company dedicated to transforming the treatment of painful and debilitating orthopedic conditions through a new class of multi-protein biologic therapeutics. Founded in 2023 and headquartered in the Greater Boston area. For more information, visit www.consanobio.com. Contacts: Consano Bio Rahul Bansal VP, Finance & Investor Relations [email protected] (908) 230-6689 Investor Relations Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 [email protected] Media Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 [email protected]

The release as fetched from its publisher. consanobio.com ↗